08:56 AM EST, 11/14/2025 (MT Newswires) -- Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) down 0.4% and the iShares Biotechnology ETF (IBB) 0.3% lower.

Bristol-Myers Squibb ( BMY ) stock was down nearly 5% after the company and Johnson & Johnson ( JNJ ) said they decided to stop a phase 3 trial of their experimental drug, milvexian, added to the standard of care for patients recovering from a recent acute coronary syndrome event. Johnson & Johnson ( JNJ ) shares were up 0.2%.